Kerin N Z, Aragon E, Marinescu G, Faitel K, Frumin H, Rubenfire M
Department of Medicine, Sinai Hospital of Detroit, Mich 48235-2899.
Arch Intern Med. 1990 Feb;150(2):381-4. doi: 10.1001/archinte.150.2.381.
The antiarrhythmic efficacy of mexiletine hydrochloride (Mexitil) was evaluated in 100 patients with potentially lethal and drug-resistant ventricular arrhythmia. The efficacy of arrhythmia suppression was assessed by Holter monitoring. The overall arrhythmia suppression of ventricular premature contractions of 70% and greater was low and seen in only 22% of patients, with an additional 16% responding to a combination of mexiletine and an additional antiarrhythmic drug. The suppression of high-grade forms, couplets of 90% and greater, and complete abolition of nonsustained runs of ventricular tachycardia was achieved in 22% of patients, with 9% responding to the addition of another antiarrhythmic agent. Ventricular premature contractions, couplets, and nonsustained ventricular tachycardia were suppressed in only 16% of the cohort. The drug was poorly tolerated, with intolerable side effects developing in 49% of patients receiving mexiletine alone and in 57% of patients receiving a combination of antiarrhythmic agents. Tolerable adverse effects were relatively common but transient and dose related.
对100例有潜在致死性和耐药性室性心律失常的患者评估了盐酸美西律（慢心律）的抗心律失常疗效。通过动态心电图监测评估心律失常抑制效果。室性早搏抑制率达70%及以上的总体情况较低，仅22%的患者出现，另有16%的患者对美西律与另一种抗心律失常药物联合用药有反应。22%的患者实现了对高级别形式、90%及以上的成对室性早搏以及非持续性室性心动过速的完全消除，9%的患者对加用另一种抗心律失常药物有反应。仅16%的队列患者的室性早搏、成对室性早搏和非持续性室性心动过速得到抑制。该药物耐受性差，单独接受美西律治疗的患者中有49%出现无法耐受的副作用，接受抗心律失常药物联合治疗的患者中有57%出现无法耐受的副作用。可耐受的不良反应相对常见，但为短暂性且与剂量相关。
